Scarica l'app Stockscreener
4.23
5.58%
-0.25
Pre-mercato:
4.25
0.02
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$4.48
Aprire:
$4.51
Volume 24 ore:
2.11M
Relative Volume:
0.78
Capitalizzazione di mercato:
$462.65M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-1.6332
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
-18.50%
1M Prestazione:
+24.05%
6M Prestazione:
-32.96%
1 anno Prestazione:
-33.49%
Intervallo 1D:
$4.17
$4.59
Intervallo di 1 settimana:
$4.05
$5.26
Portata 52W:
$2.8647
$9.305
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta VERV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
4.23 | 462.65M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-10-06 | Iniziato | Credit Suisse | Neutral |
| 2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-07-12 | Iniziato | Guggenheim | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Neutral |
| 2021-07-12 | Iniziato | Jefferies | Buy |
| 2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Expands Team: 7 New Hires Receive Major Equity Package Worth $1.1M - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - Yahoo Finance
Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Why Verve Therapeutics Zoomed 40% Higher This Week - MSN
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - MSN
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' - Seeking Alpha
Verve Therapeutics (VERV) Stock Soars on Positive Trial Results - GuruFocus
Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - MSN
Verve impresses investors with second shot at PCSK9 - BioCentury
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verve Therapeutics Inc Azioni (VERV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '25 |
Sale |
4.15 |
2,777 |
11,525 |
17,420 |
| Ashe Andrew D. | See Remarks |
Apr 02 '25 |
Sale |
4.15 |
2,681 |
11,126 |
348,828 |
| Politi Jason | Chief Technical Ops. Off. |
Apr 02 '25 |
Sale |
4.15 |
3,235 |
13,425 |
14,226 |
| Dorval Allison | Chief Financial Officer |
Apr 02 '25 |
Sale |
4.15 |
3,350 |
13,903 |
13,280 |
| Lister Troy | Chief Scientific Officer |
Apr 02 '25 |
Sale |
4.15 |
2,189 |
9,084 |
6,952 |
| Dorval Allison | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.64 |
555 |
3,130 |
5,380 |
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):